1. Home
  2. ATOS vs STRO Comparison

ATOS vs STRO Comparison

Compare ATOS & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$0.82

Market Cap

100.8M

Sector

Health Care

ML Signal

HOLD

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$9.83

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATOS
STRO
Founded
2009
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.8M
94.9M
IPO Year
2012
2018

Fundamental Metrics

Financial Performance
Metric
ATOS
STRO
Price
$0.82
$9.83
Analyst Decision
Strong Buy
Hold
Analyst Count
3
7
Target Price
$6.33
$19.67
AVG Volume (30 Days)
911.6K
110.9K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$105,646,000.00
Revenue This Year
N/A
$62.61
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$5.23
52 Week High
$1.29
$24.80

Technical Indicators

Market Signals
Indicator
ATOS
STRO
Relative Strength Index (RSI) 51.07 88.38
Support Level $0.68 $7.88
Resistance Level $0.99 $9.38
Average True Range (ATR) 0.05 0.63
MACD 0.02 0.73
Stochastic Oscillator 44.30 97.12

Price Performance

Historical Comparison
ATOS
STRO

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Share on Social Networks: